Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

Teva previously filed a separate lawsuit against Mylan in October 2009 for infringement of multiple patents, including all seven Orange Book patents, covering the chemical composition of COPAXONE®, pharmaceutical compositions containing it, methods of using it and processes for making it. Those patents expire in May 2014 and September 2015. No trial date is scheduled.

Source:
Teva Pharmaceutical Industries Ltd.

View drug information on Copaxone.